The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment with a platinum-containing chemotherapy, the U.S. Food and Drug Administration announced Thursday.